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Since more than 10 years, the word PROTEOME catches the attention of more 
and more researchers in the life science field. At about the same time the term high 
throughput proteome analysis came up with the intention to analyse all proteins in a 
complex protein mixture in parallel. Thus, a huge amount of data can be produced from 
a single sample and the following analysis and validation becomes the time limiting 
step. However, the limited number of available biomarkers for diagnosis, status of the 
disease, therapy control and prediction of the course of the disease demands for new 
efforts in finding new ones. Especially, proteomics raises high expectations in finding 
new and reliable biomarker for human diseases.
Hepatic cirrhosis is a life-threatening disease arising from different chronic liver 
disorders. Major causes for hepatic cirrhosis are chronic hepatitis B&C infection or 
abuse of alcohol. Chronic hepatitis C causes at least ~20% developing liver cirrhosis 
within 40 years. To date only liver biopsy allows a reliable evaluation of the course of 
hepatitis C by grading inflammation and staging fibrosis, and thus serum biomarkers 
for hepatic fibrosis with high sensitivity and specificity are needed.
In order to identify new candidate biomarkers for hepatic fibrosis, we performed a 
proteomic approach of microdissected cirrhotic septa and liver parenchyma cells. In 
cirrhotic septa we detected an increasing expression of cell structure associated proteins 
including actin, tropomyosin, calponin, transgelin and human microfibril associated 
glycoprotein 4 (MFAP-4). The expression of tropomyosin, transgelin and MFAP-4, an 
extracellular matrix associated protein, were further evaluated by immunohistochemistry. 
Tropomyosin and microfibril associated glycoprotein 4 demonstrated high serum 
levels in patients with hepatic cirrhosis of different etiologies. A quantitative analysis of 
MFAP-4 serum levels in a large number of patients (n=130) revealed MFAP-4 as novel 
candidate biomarker with high diagnostic accuracy for prediction of non-diseased liver 
vs cirrhosis as well as stage 0 vs stage 4 fibrosis.
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Thus, high performance proteomics is the basic principle for reliable results 
which allows us to discover new biomarker candidates for liver cirrhosis using minute 
amounts of patients’ material. How to reach this goal will be presented in the lecture.
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